First results of a dose-escalation study evaluating <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).

Miguel Zugman, Alex Chehrazi-Raffle, Xiaochen Li et al.|Journal of Clinical Oncology|2026

Cited by 0